Skip to main content
Donate

Industry

News

An Update on the ION582 clinical development program including HALOS, REVEAL, and CHAMPION Trials

Ionis Pharmaceuticals has shared a letter to the Angelman syndrome community on the ION582 clinical development program. The letter covers progress on the Phase 1/2 HALOS and Phase 3 REVEAL trials, as well as the recently announced CHAMPION trial to explore ION582 in additional genotypes.

Read the letter: https://bit.ly/48WCeNK

Related

Voice of the Patient Report Submitted: A Powerful Milestone for the Angelman Syndrome Community
FAST × ASA Angelman Syndrome Clinical Trials Webinar: Europe/UK Sites, Eligibility, and How to Join Trials
MavriX Bio MVX-220 Update
Ultragenyx Receives Breakthrough Therapy Designation for GTX-102 in Angelman Syndrome

View All News

Disclaimer

This website contains information for a broad audience and may include information on current and upcoming programs that are not yet approved or accessible The information provided is for general informational purposes only and is not intended as medical advice, diagnosis, or treatment. While FAST strives to provide accurate and up-to-date information, the content on this site may not always reflect the most current research or clinical guidelines. The inclusion of clinical trial information, treatments or specific healthcare providers does not imply endorsement, recommendation or guarantee of safety, efficacy, or availability. Reliance on any information provided by this website is solely at your own risk. FAST disclaims any liability for any errors or omissions in the information provided or for any decisions made based on this information. For personalized medical advice or specific health concerns including participation in any clinical trial, please consult a qualified healthcare professional.